Revenue grew 9% year-over-year to 681.3 mln PLN, with EBITDA up 24% and net profit up 24%. The group saw strong recurring revenue growth in medical equipment and IT, stable radio-pharmaceuticals EBITDA, and a strategic spin-off of the R&D/cardio business.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.